Skip to content

Zantac and Cancers: What Types of Cancer May Zantac Cause in Patients?

Oct 28, 2020
Shamis & Gentile, P.A.
Cancer linked to Roundup

In April of 2020, the FDA asked manufacturers of ranitidine medications, including the popular medication Zantac, to recall their products due to the presence of elevated levels of NDMA, also known as N-Nitrosodimethylamine. NDMA is considered to be a probable carcinogenic compound which may lead to an increased risk for certain types of cancers.

There are currently multiple Zantac lawsuit investigation actions in effect due to this potential link between Zantac and cancers. If you or a loved one has taken Zantac and you have been diagnosed with one or more cancers, please consider the following information about what types of cancers may be linked to taking Zantac.

Zantac is a popular medication primarily used to treat heartburn, although Zantac has also been used to treat reflux diseases and similar conditions. Zantac is the brand name for ranitidine. The brand Zantac was produced by Sanofi.

Why Are Zantac Lawyers Seeking Lawsuits?

In 2019, the independent online pharmacy Valisure conducted a lab test of ranitidine products and found that every lot tested had an excessive amount of NDMA. According to their lab findings, one single dosage of Zantac was 3000 times the maximum recommended daily intake of NDMA. The Zantac lawsuit lawyers are seeking investigations due to the fact that this unacceptable level of NDMA may be linked to cancers; some lawsuits also allege that Sanofi knew about the presence of high levels of NDMA but did not warn consumers.

What Types of Cancers May Zantac Cause?

The NDMA present in Zantac may be linked to specific types of cancers and tumor development. Studies have found that renal, pulmonary and hepatic tumors are increased along with the consumption of NDMA; studies on the impact of NDMA on the development for certain cancers founds that both single doses and long-term exposure to NDMA consumption can increase the risk.

Some of the specific cancers linked to NDMA exposure include the following:

  • Esophageal cancer
  • Stomach cancer
  • Colorectal cancer
  • Kidney cancer
  • Cancer in the small intestine
  • Cancer in the large intestine
  • Liver cancer
  • Bladder cancer
  • Pancreatic cancer
  • Non-Hodgkin’s lymphoma
  • Multiple myeloma
  • Leukemia
  • Breast cancer
  • Throat or nasal cancer
  • Brain cancer
  • Islet cell tumors

There are multiple ongoing Zantac lawsuit investigation actions which are seeking to determine the frequency of certain types of cancers and their potential connection to Zantac and other ranitidine medications. Some of these studies include a focus on liver cancer, bladder cancer, as well as breast cancer.

In their own tests, the FDA found that the amount of NDMA inside ranitidine products increases over time due to the potential instability of ranitidine; this NDMA level increases even if the ranitidine is stored at room temperature and in otherwise stable, safe conditions.

Contact Zantac Lawyers Today

If you have taken Zantac and were later diagnosed with one or more cancers, please contact your Zantac Lawyers, Shamis & Gentile, P.A. for a free case review at Or you can call us today 305-479-2299.

Submit a Class Action Claim

Submit a class action claim today; there are no associated fees or expenses unless we manage to win the case on your behalf.